David Gamm on Stem Cell Research Dr. David Gamm, associate professor of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health in Madison and director of the McPherson Eye Research Institute, discusses the use of stem cells for eye diseases.From:UWMedicineViews:16 0ratingsTime:03:15More inEntertainment Read the original post: David Gamm on Stem Cell Research - Video … Continue reading →

Perceptions of Promise art show opens at UAlberta Perceptions of Promise, the visionary University of Alberta art show that created an interdisciplinary dialogue between artists and scientists, has come home after a successful run that included a high-profile exhibition in New York. "We're so happy that it's finally come home," said U of A printmaking professor Liz Ingram. "Our students can now see it, and that is so important for teaching." The exhibition explores legal, ethical and social issues about stem-cell research through the eyes of U of A and other internationally known artists. Originally conceived by Sean Caulfield, U of A professor of printmaking, and his brother Tim, research director of the U of A's Health Law and Science Policy Group, it brings scientists and visual artists together to broaden discussion of complex topics involving biotechnology. The aim, say contributors, is not to take positions on either side of what can often be a divisive debate, but to provoke thought and inspire questions. "Biomedical research, especially stem-cell research, tends to be very emotional," says Sean Caulfield. "People have this polarized reaction to it. If we had one broad objective, it would be to see how art … Continue reading →

Dr. Tommy Mitchell Stem Cells Cloning Immanuel Baptist Church Highland, CA. November 5, 2012 At 44:00 Min he accidentally says "Is using Adult Stem Cells Wrong? Yes. He should have said Embryonic Stem Cells. ; ) Dr. Tommy Mitchell Lecture on Stem Cells Cloning at Immanuel Baptist Church Highland, CA. November 5, 2012 Dr. Mitchell graduated with a BA with highest honors from the University of Tennessee, Knoxville, in 1980, with a major in Cell Biology and a minor in Biochemistry. For his superior scholarship during his undergraduate study, he was elected to Phi Beta Kappa Society (the oldest and one of the most-respected honor societies in America). Dr. Mitchell subsequently attended Vanderbilt University School of Medicine in Nashville, where he received his medical degree in 1984. Dr. Mitchell completed his residency at Vanderbilt University Affiliated Hospitals in 1987. He is Board Certified in Internal Medicine. In 1991, he was elected a *Fellow of the American College of Physicians (FACP). Tommy had a thriving medical practice in his hometown of Gallatin, Tennessee, for 20 years, but, in late 2006, he withdrew from medical practice to pursue creation ministry full time.From:MClover420Views:0 0ratingsTime:01:00:01More inEducation View post: Dr. Tommy Mitchell Stem Cells … Continue reading →

90 DAYS, 90 REASONS #79 Because President Obama Supports Stem Cell Research Romney, meanwhile, has managed to stake out equivocating, obfuscating, and disingenuous stances on the issue. The anti-choice right wing, which defines stem cell research as an equivalent to abortion, believes that Romney shares their extremist position. Romney himself claims to support the "scientific alternative," known as iPS, without acknowledging mdash;or could he somehow not know? mdash;that iPS requires stem cell research to progress; the two presently go hand in hand, or not at all.From:vidhead85Views:0 0ratingsTime:02:44More inNews Politics Read more here: 90 DAYS, 90 REASONS #79 Because President Obama Supports Stem Cell Research - Video … Continue reading →

American cardiologist and researcher Dr. Yerem Yeghiazarians is currently on a visit to the Kingdom to gauge interest in setting up a stem-cell research facility here. Leading Saudi businessmen Hamad and Khalid Al-Zamil are interested in advancing the research initiative and invited Dr. Yeghiazarians to meet business leaders, arranged lectures and toured him around various hospitals to garner support for his pioneering project. Dr. Yeghiazarians believes stem cell treatment may be the only hope for thousands of people worldwide who suffer from heart problems. "It would be fantastic if we could set up a research program here. I am trying to monitor the interest among people here. I need to know what facilities are currently available and find out how we can introduce larger facilities to the region to advance the research collaboratively," he told Arab News in an interview. "My mission is to educate people here about stem cell research, heart diseases, heart failure and the potential treatment we can offer our patients," said Dr. Yeghiazarians. In the US alone, he pointed out that there are about 1.5 million heart attacks every year, and one in five people are going to die from heart disease. There are over three … Continue reading →

TORONTO, ONTARIO--(Marketwire - Nov. 7, 2012) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network ("UHN"), through its commercialization agent MaRS Innovation ("MI"), both of Toronto. The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program. Based on Dr. Aaron Schimmer's award-winning research, the technology has provided compelling evidence that tigecycline, an FDA-approved antibiotic, is able to selectively target leukemia cells and leukemic stem cells by shutting down their energy supply through the inhibition of mitochondrial protein synthesis. Dr. Schimmer, Associate Professor in the University of Toronto's Department of Medical Biophysics and a clinician-scientist in the Princess Margaret Cancer Centre/Ontario Cancer Institute at University Health Network, published his findings in 2011 in the journal Cancer Cell. Based on this discovery, Dr. Schimmer received the 2012 Till & McCulloch Award presented each year by the Stem Cell Network to recognize the year's most influential peer-reviewed article by a researcher in Canada. "In recent years Dr. Schimmer has had a widely-recognized rise to become one of Canada's premier clinician-scientists," commented David Allan, Executive … Continue reading →

NEWARK, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the third quarter ended September 30, 2012 and provided a business update. "We remain committed to building shareholder value by generating meaningful preclinical and clinical data in a cash-efficient manner," said Martin McGlynn, President and CEO of StemCells, Inc. "As to meaningful data, we recently published two papers demonstrating the therapeutic potential of our proprietary HuCNS-SC(R) cells for a range of myelination disorders, including the data from our Phase I clinical trial in Pelizaeus-Merzbacher disease showing evidence of new myelination and measurable gains in neurological function; we reported interim data from our spinal cord injury trial showing considerable gains in sensory function in two of three patients compared to pre-transplant baselines; and we reported exciting preclinical data in two animal models relevant to Alzheimer's disease. The data we are generating and reporting illustrate the considerable potential of our HuCNS-SC human neural stem cells to address a broad range of CNS disorders. "As to cash management, we continue to look for ways to … Continue reading →